Exploring 3 High Growth Tech Stocks in the United States

In This Article:

Over the last 7 days, the United States market has risen by 5.7%, contributing to a remarkable increase of 37% over the past year, with earnings anticipated to grow by 16% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

AsiaFIN Holdings

51.75%

58.17%

★★★★★★

Invivyd

47.87%

67.72%

★★★★★★

Sarepta Therapeutics

23.89%

42.65%

★★★★★★

TG Therapeutics

34.66%

56.48%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Alnylam Pharmaceuticals

22.45%

70.66%

★★★★★★

Blueprint Medicines

25.26%

68.92%

★★★★★★

Travere Therapeutics

31.20%

72.26%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 243 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

CleanSpark

Simply Wall St Growth Rating: ★★★★★☆

Overview: CleanSpark, Inc. operates as a bitcoin miner in the Americas with a market cap of $3.50 billion.

Operations: The company generates revenue primarily through its Bitcoin Mining Business, which reported $342.21 million. The focus on bitcoin mining highlights a concentrated revenue stream within the digital currency sector.

CleanSpark, showcasing resilience and adaptability, recently resumed operations post-Hurricane Helene with a hashrate rebound to 28.7 EH/s, underscoring its robust recovery mechanisms. Amidst operational updates, the company also expanded its financial flexibility by doubling authorized shares to 600 million, reflecting potential for future growth initiatives or equity-based financing. Financially, CleanSpark is poised for significant growth with revenue expected to surge at an annual rate of 37.2%, outpacing the broader US market's 8.9%. Moreover, earnings are projected to skyrocket by approximately 83.4% annually over the next three years, indicating strong future profitability despite current unprofitability and recent shareholder dilution.

NasdaqCM:CLSK Revenue and Expenses Breakdown as at Nov 2024
NasdaqCM:CLSK Revenue and Expenses Breakdown as at Nov 2024

TG Therapeutics

Simply Wall St Growth Rating: ★★★★★★

Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases globally, with a market cap of $4.13 billion.

Waiting for permission
Allow microphone access to enable voice search

Try again.